Developing a new treatment for Alzheimer's disease using EP2 receptor antagonists
Development of EP2 Receptor Antagonist to Treat Alzheimer's Disease
This study is testing a new medication that could help people with Alzheimer's by reducing brain inflammation and amyloid buildup, which may help keep their thinking skills sharper.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10944958 on NIH RePORTER |
What this research studies
This research focuses on creating a new type of medication aimed at treating Alzheimer's disease by targeting the EP2 receptor, which plays a significant role in neuroinflammation associated with the disease. The approach involves developing small-molecule antagonists that can block this receptor, potentially reducing inflammation and amyloid buildup in the brain. The research has shown promising results in animal models, indicating that this treatment could help preserve cognitive function in patients. By validating this novel mechanism, the study aims to provide a new therapeutic option for those affected by Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
Not a fit: Patients with other types of dementia or cognitive impairments unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that slows the progression of Alzheimer's disease and improves cognitive function in patients.
How similar studies have performed: Previous research has shown success with similar approaches targeting neuroinflammation in Alzheimer's, but this specific mechanism is relatively novel.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Ganesh, Thota — Emory University
- Study coordinator: Ganesh, Thota
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.